Menu
Back to User profile » Prof. Dr. In-Jin Jang
Papers published by Prof. Dr. In-Jin Jang:
A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
Kim HC, Lee S, Sung S, Kim E, Jang IJ, Chung JY
Drug Design, Development and Therapy 2023, 17:1203-1210
Published Date: 21 April 2023
Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects
Kim HC, Yang E, Ban MS, Kim YK, Hong SH, Jung J, Jang IJ, Lee S
Drug Design, Development and Therapy 2023, 17:1115-1124
Published Date: 12 April 2023
Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole
Bae S, Kwon J, Lee SB, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2021, 15:5099-5108
Published Date: 21 December 2021
Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects
Hwang S, Lee DY, Cho JY, Chung JY, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2021, 15:2375-2384
Published Date: 1 June 2021
Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
Jeon I, Oh J, Kwon YK, Yoon SH, Cho JY, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2021, 15:1735-1747
Published Date: 28 April 2021
Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study
Yang E, Yoo H, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2021, 15:651-658
Published Date: 17 February 2021
Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects
Yoo H, Kim Y, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2020, 14:5179-5187
Published Date: 24 November 2020
Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
Hwang I, Kim Y, Yoo H, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2020, 14:4493-4502
Published Date: 23 October 2020
Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers
Yoon DY, Park SI, Jung JA, Kim YI, Jang IJ, Chung JY
Drug Design, Development and Therapy 2020, 14:661-668
Published Date: 19 February 2020
A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects
Kim E, Park KR, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2019, 13:3879-3885
Published Date: 13 November 2019
Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers
Choi Y, Lee S, Jang IJ, Yu KS
Drug Design, Development and Therapy 2018, 12:2301-2309
Published Date: 24 July 2018
Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese
Choi Y, Yoon S, Matsumoto K, Ohta Y, Lee S, Yu KS, Jang IJ
Drug Design, Development and Therapy 2018, 12:1045-1051
Published Date: 30 April 2018
Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects
Kim YK, Shin KH, Alderman J, Yu KS, Jang IJ, Lee S
Drug Design, Development and Therapy 2018, 12:331-337
Published Date: 19 February 2018
Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H:quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials
Kim S, Lee S, Cho JY, Yoon SH, Jang IJ, Yu KS
Drug Design, Development and Therapy 2017, 11:3187-3195
Published Date: 7 November 2017
Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects
Shin D, Lee S, Yi S, Yoon SH, Cho JY, Bahng MY, Jang IJ, Yu KS
Drug Design, Development and Therapy 2017, 11:713-723
Published Date: 10 March 2017
Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study
Choi Y, Lee S, Cho SM, Kang WH, Nam KY, Jang IJ, Yu KS
Drug Design, Development and Therapy 2016, 10:3021-3028
Published Date: 20 September 2016
The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan
Gu N, Cho JY, Shin KH, Jang IJ, Rhee MY
Drug Design, Development and Therapy 2016, 10:1525-1531
Published Date: 19 April 2016
Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects
Rhee SJ, Lee S, Yoon SH, Cho JY, Jang IJ, Yu KS
Drug Design, Development and Therapy 2016, 10:1411-1418
Published Date: 13 April 2016
Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects
Yoon S, Shin D, Lee H, Jang IJ, Yu KS
Drug Design, Development and Therapy 2015, 9:5033-5049
Published Date: 31 August 2015
A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles
Chung H, Lee H, Han H, An H, Lim KS, Lee YJ, Cho JY, Yoon SH, Jang IJ, Yu KS
Drug Design, Development and Therapy 2015, 9:2609-2616
Published Date: 13 May 2015
A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects
Park SI, Lee H, Oh J, Lim KS, Jang IJ, Kim JA, Jung JH, Yu KS
Drug Design, Development and Therapy 2015, 9:729-736
Published Date: 4 February 2015
Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study
Kim S, Lee J, Shin D, Lim KS, Kim YS, Jang IJ, Yu KS
Drug Design, Development and Therapy 2014, 8:1723-1731
Published Date: 6 October 2014
Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
Gu N, Park MK, Kim TE, Bahng MY, Lim KS, Cho SH, Yoon SH, Cho JY, Jang IJ, Yu KS
Drug Design, Development and Therapy 2014, 8:1709-1721
Published Date: 6 October 2014
Novel nanocrystal formulation of megestrol acetate has improved bioavailability compared with the conventional micronized formulation in the fasting state
Jang K, Yoon S, Kim SE, Cho JY, Yoon SH, Lim KS, Yu KS, Jang IJ, Lee H
Drug Design, Development and Therapy 2014, 8:851-858
Published Date: 25 June 2014
Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers
Yoon S, Lee H, Kim TE, Lee S, Chee DH, Cho JY, Yu KS, Jang IJ
Drug Design, Development and Therapy 2014, 8:123-128
Published Date: 15 January 2014